Clinical Trial Update: Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating implanted autologous skeletal muscle cells from the thigh into scarred heart tissue after a heart attack was terminated. The sponsor li…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Cardiomyopathy
• Ischemic Heart Disease
• Ischemic Heart Failure

Drugs mentioned

• Autologous skeletal muscle cell implants

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Ischemic Heart Failure, Ischemic Heart Disease | Phase 2 | Status: TERMINATED